NLRP3 Inflammasome as a Potential Therapeutic Target in Dry Eye Disease
International Journal of Molecular Sciences · 29.06.2023 · 24 (13) · 10866
DOI: 10.3390/ijms241310866 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.06.2023. Verfasst von Dian Zhuang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New …. Hauptthemen laut MEDLINE: Inflammasomes, Dry Eye Syndromes. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand, New Zealand Optometric Vision Research Foundation, Buchanan Charitable Foundation.
Abstract (Originalsprache)
Dry eye disease (DED) is a multifactorial ocular surface disorder arising from numerous interrelated underlying pathologies that trigger a self-perpetuating cycle of instability, hyperosmolarity, and ocular surface damage. Associated ocular discomfort and visual disturbance contribute negatively to quality of life. Ocular surface inflammation has been increasingly recognised as playing a key role in the pathophysiology of chronic DED. Current readily available anti-inflammatory agents successfully relieve symptoms, but often without addressing the underlying pathophysiological mechanism. The NOD-like receptor protein-3 (NLRP3) inflammasome pathway has recently been implicated as a key driver of ocular surface inflammation, as reported in pre-clinical and clinical studies of DED. This review discusses the intimate relationship between DED and inflammation, highlights the involvement of the inflammasome in the development of DED, describes existing anti-inflammatory therapies and their limitations, and evaluates the potential of the inflammasome in the context of the existing anti-inflammatory therapeutic landscape as a therapeutic target for effective treatment of the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New Zealand.
- Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New Zealand.
ORCID-Profile: Dian Zhuang, Stuti L Misra, Odunayo O Mugisho, Ilva D Rupenthal, Jennifer P Craig
Förderung
- Health Research Council of New Zealand
- New Zealand Optometric Vision Research Foundation
- Buchanan Charitable Foundation
- Neurological Foundation of New Zealand First Fellowship
- Auckland Medical Research Foundation Project Grant
Zitieren
APA
Zhuang, D., Misra, S. L., Mugisho, O. O., Rupenthal, I. D., & Craig, J. P. (2023). NLRP3 Inflammasome as a Potential Therapeutic Target in Dry Eye Disease. International Journal of Molecular Sciences, 24(13), 10866. https://doi.org/10.3390/ijms241310866
Vancouver
Zhuang D, Misra SL, Mugisho OO, Rupenthal ID, Craig JP. NLRP3 Inflammasome as a Potential Therapeutic Target in Dry Eye Disease. International Journal of Molecular Sciences. 2023;24(13):10866. doi:10.3390/ijms241310866
BibTeX
@article{Zhuang2023,
author = {Zhuang, Dian and Misra, Stuti L and Mugisho, Odunayo O and Rupenthal, Ilva D and Craig, Jennifer P},
title = {NLRP3 Inflammasome as a Potential Therapeutic Target in Dry Eye Disease},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {13},
pages = {10866},
doi = {10.3390/ijms241310866}
}
EUVIMED